NeuroCatch

NeuroCatch Inc., a subsidiary of HealthTech Connex, has developed the NeuroCatch Platform, an industry-leading medical device that provides a rapid, objective evaluation of cognitive brain function at the point of care. Approved by Health Canada as a Class II medical device in 2019, the NeuroCatch Platform utilizes brainwave (electro-encephalography or EEG) sensors embedded in a mesh cap to deliver standardized medical-grade results in minutes.

The platform consists of a custom hardware/software system that translates evoked brain responses into intuitive radar plots. These plots can be compared to prior scans, enabling healthcare practitioners to monitor changes in cognitive function over time. The technology is designed to aid in the evaluation of various conditions, including brain injuries, neurological disorders, mental health issues, and cognitive optimization.

The latest generation of the NeuroCatch Platform, approved by Health Canada in September 2022, offers significant advancements. It features a cloud-based platform providing real-time access to radar plots displaying the largest published normative reference value datasets. Additionally, an innovative EPiO Adapter provides a 10-15 times improvement in temporal precision and sensitivity, enabling the detection of subtle but significant changes in brain function when monitoring neurological conditions like concussions and brain injuries.

The NeuroCatch Platform is rapidly gaining adoption across Canada and the US for both clinical and research applications. It is currently being utilized in various studies and treatment programs, including concussion research with youth hockey and football players, long-haul COVID brain fog treatment, and investigations into breakthrough treatments, preventative options, and adverse outcome prediction for concussions. Leading institutions like the Alberta Children's Hospital and Weill Cornell Medicine at Cornell University are also utilizing NeuroCatch to improve clinical care for severe brain injuries.

Key customers and partnerships

The NeuroCatch Platform has been widely adopted by healthcare practitioners, researchers, and peak performers across Canada and the US. Notable customers and partners include:

- Mayo Clinic: Conducted groundbreaking concussion research studies with youth hockey players.

- Sanford Clinic: Led concussion research studies with youth football players.

- Surrey Neuroplasticity Clinic: Utilizes NeuroCatch in a long-haul COVID brain fog treatment program.

- Alberta Children's Hospital and the University of Calgary: Employing NeuroCatch in concussion research examining children with mild traumatic brain injuries.

- Weill Cornell Medicine at Cornell University: Leveraging NeuroCatch to improve clinical care for severe brain injuries.

Healthcare professionals and researchers from various institutions, such as Advantage four Athletes, Apollo Physical Therapy Centres, Novah healthcare, and the University of Victoria, have also incorporated NeuroCatch into their clinical practices and research endeavors.